

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Johnson et al

Docket No.

00963/1

Serial No.

10/634,581

Filing Date

8/5/03

Examiner

Unknown

Group Art Unit

Unknown

Invention: Stable pH Optimized Formulation of a ~~Modified~~ AntibodyI hereby certify that this Ids References, Ids Form 1449, Ids Response, Postcard

(Identify type of correspondence)


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 11/10/2003

(Date)

Michelle R. Becker

(Typed or Printed Name of Person Mailing Correspondence)



(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of
Johnson, et al.

Serial No. 10/634,581

Filed: August 5, 2003

)
)
)
)
)

Attorney Docket No. 00963/1

Group Art Unit: Unknown

Examiner: Unknown

For STABLE ph OPTIMIZED FORMULATION OF A MODIFIED ANTIBODY

November 10, 2003

Commissioner of Patents
PO Box 1450
Alexandria, VA 22313

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,

James M. Warner, Reg. No. 45,199
Attorney for Applicants
(314) 274-3642 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63006



Sheet 1 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 00963/1	APPLICATION NO.: 10/634,581
	INVENTOR: Johnson, et al.	
	Filed: 8/5/03	Group:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6,248,471					
	6,258,562					
	5,654,407					
	6,090,923					
	5,795,697					
	6,267,958					
	4,640,835					
	4,496,689					
	4,301,144					
	4,670,417					
	4,791,192					
	6,113,906					
	5,919,455					
	5,643,575					
	5,932,462					
	6,171,586					
	4,816,567					

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	1	01/94585		PCT				
	2	788515		EP				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



(Form PTO-1449)

Sheet 2 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 00963/1	APPLICATION NO.: 10/634,581
	INVENTOR: Johnson, et al.	
	Filed: 8/5/01	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	3	Meager et al; Hybridoma; 6; 305-311; 1987
	4	Fendly et al; 6; 359-370; 1987
	5	Shimamoto et al; Immunology Letters; 17; 311-318; 1988
	6	Rankin et al ; British J. Rheumatology ; 34 ; 334-342 ; 1995
	7	Pikal, M.; biopharm; 3(9); 26-30; 1990
	8	Arkawa et al; Pharm Res; 8(3); 285-291; 1991
	9	Stratton, Lewis et al; J of Pharm Sci; 90(12); 2141-2148; Dec 2001
	10	Chapman, Andrew P. et al; Nature Biotechnology; 17; 780-783; August 1999
	11	Ishi, Yoshiharu et al; Biophys J.; 50; 75-80; July 1986
	12	Kohler et al; Nature; 256; 495; 1975
	13	Clackson et al; Nature; 352; 624-628; 1991
	14	Marks et al; J. Mol. Biol.; 222; 581-597; 1991
	15	Morrison et al; Proc Natl Acad Sci USA; 81; 6851-6855; 1984
	16	Jones et al; Nature; 321; 522-525; 1986
	17	Reichmann et al; Nature; 332; 323-329; 1988
	18	Presta; Curr Op Struct Biol.; 2; 593-596; 1992

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)